Product Categories
| Country: | United States |
|---|---|
| Tel: | 781-+1-781-999-5354 |
| Mobile: | +1-00000000000 |
| E-mail: | info@targetmol.com |
| QQ: | |
| Skype: | Chat Now! |
| Address: | 36 Washington Street, Wellesley Hills |
|
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
|
|
| Product Name | MF | CAS | Details |
|---|
| OMDM-1；(Z)-N-[(2S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]octadec-9-enamide | C27H45NO3 | 616884-62-9 | Details |
| OMDM-2 | C27H45NO3 | 616884-63-0 | Details |
| OMDM-6 | C28H42N2O3 | 616884-67-4 | Details |
| OMDM-3 | C29H43NO3 | 616884-64-1 | Details |
| OMDM-4 | C29H43NO3 | 616884-65-2 | Details |
| OMDM-5 | C26H44N2O3 | 616884-66-3 | Details |
| Ophiobolin B | C25H38O4 | 5601-74-1 | Details |
| Opioid receptor modulator 1 | C18H23NO2 | 77514-44-4 | Details |
| OP-1074 | C29H31NO4 | 1443752-76-8 | Details |
| Omeprazole-d3；H 16868 D3;Omeprazole D3 | C17H16D3N3O3S | 922731-01-9 | Details |
| Pilocarpine nitrate；Pilofrin;Pilagan | C11H17N3O5 | 148-72-1 | Details |
| ON 146040 | C24H23N7O3S | 1404231-34-0 | Details |
| Omeprazole metabolite Omeprazole sulfone；Omeprazole sulphone;Omeprazole sulfone | C17H19N3O4S | 88546-55-8 | Details |
| Tirabrutinib hydrochloride；GS-4059 (hydrochloride);ONO-4059 (hydrochloride) | C25H23ClN6O3 | 1439901-97-9 | Details |
| ORM-10103 | C20H16N2O4 | 488847-28-5 | Details |
| Orelabrutinib；ICP-022 | C26H25N3O3 | 1655504-04-3 | Details |
| Oral antiplatelet agent 1 | C23H24N4O5S | 2299200-91-0 | Details |
| OR-1896 | C13H15N3O2 | 220246-81-1 | Details |
| Org30958 | C21H30O2S2 | 99957-90-1 | Details |
| OSMI-3 | C32H35N3O9S2 | 2260791-13-5 | Details |
| ORM-15341 | C19H17ClN6O2 | 1297537-33-7 | Details |
| Mepyramine maleate；Pyrilamine maleate | C21H27N3O5 | 59-33-6 | Details |
| ORM-10962 | C27H29N3O4 | 763926-98-3 | Details |
| OSMI-4 | C27H26ClN3O7S2 | 2260791-14-6 | Details |
| Ornidazole (Levo-)；(S)-Ornidazole;Levornidazole | C7H10ClN3O3 | 166734-83-4 | Details |
| ORL1 antagonist 1 | C20H22ClN5 | 1174985-59-1 | Details |
| Orotic acid-6-C14 | C5H4N2O4 | 13186-54-4 | Details |
| Oxolinic acid；Dioxacin;Urinox;Emyrenil;Nidantin;NSC 110364 | C13H11NO5 | 14698-29-4 | Details |
| Org-10490 | C17H19NO | 83507-02-2 | Details |
| OSMI-2 | C26H25N3O7S2 | 2260542-60-5 | Details |
| Oxidopamine hydrochloride；6-Hydroxydopamine hydrochloride;6-OHDA hydrochloride | C8H12ClNO3 | 28094-15-7 | Details |
| Oxythiamine diphosphate | C12H17N3O8P2S | 10497-04-8 | Details |
| Benzquinamide；BZQ;Benzoquinamide;P2647 | C22H32N2O5 | 63-12-7 | Details |
| p53 and MDM2 proteins-interaction-inhibitor (chiral)；p53-and-mdm2-proteins-interaction-inhibitor-chiral | C40H49Cl2N5O4 | 939981-37-0 | Details |
| Oxidopamine hydrobromide；6-Hydroxydopamine hydrobromide;6-OHDA hydrobromide | C8H12BrNO3 | 636-00-0 | Details |
| Paprotrain；(alphaZ)-alpha-(3-Pyridinylmethylene)-1H-indole-3-acetonitrile | C16H11N3 | 57046-73-8 | Details |
| 5,5-Dimethyloxazolidine-2,4-dione；Dimethyloxazolidinedione;Dimethadion;Dimethadione | C5H7NO3 | 695-53-4 | Details |
| OTS186935 | C25H26ClN5O2 | 2093400-18-9 | Details |
| Oxaquin；MCB-3837;DNV3837 | C31H33F2N4O11P | 790704-50-6 | Details |
| CBP/p300-IN-5；P300/CBP-IN-5 | C29H27F5N6O4 | 1889284-33-6 | Details |
| Palmitoyldocosahexaenoyl phosphatidylcholine | C46H80NO8P | 59403-54-2 | Details |
| para-Nitroblebbistatin | C18H15N3O4 | 1621326-32-6 | Details |
| OT antagonist 3 | C21H20N6O2 | 925703-75-9 | Details |
| Palonidipine | C29H34FN3O6 | 96515-73-0 | Details |
| Lincomycin hydrochloride monohydrate；Lincomycin hydrochloride hydrate | C18H37ClN2O7S | 7179-49-9 | Details |
| OXFBD04 | C17H16N2O3 | 2231747-03-6 | Details |
| OT-82 | C26H21FN4O | 1800487-55-1 | Details |
| OT-R antagonist 1；Oxytocin receptor antagonist 1 | C28H29N3O4 | 364071-17-0 | Details |
| Oxotremorine M iodide | C11H19IN2O | 3854-04-4 | Details |
| Oxythiamine；Hydroxythiamin | C12H17Cl2N3O2S | 136-16-3 | Details |
| p38α inhibitor 1 | C22H26F2N4O2 | 1034189-82-6 | Details |
| P-gp inhibitor 1 | C32H31N5O2 | 2050747-49-2 | Details |
| CBP/p300-IN-3；P300/CBP-IN-3 | C24H29N7O | 2299226-01-8 | Details |
| Palbinone | C22H30O4 | 139954-00-0 | Details |
| Palbociclib-d8；Palbociclib D8;PD 0332991 D8 | C24H21D8N7O2 | 1628752-83-9 | Details |
| p38-α MAPK-IN-1 | C27H35N5O3 | 443913-15-3 | Details |
| OT antagonist 1 | C22H22N4O3 | 479080-38-1 | Details |
| P-gp modulator 1 | C41H72N2O6 | 2249749-39-9 | Details |
| OTS186935 trihydrochloride | C25H27Cl2N5O2 | 2093401-85-3 | Details |
| Palmitoylcarnitine | C23H45NO4 | 1935-18-8 | Details |
| p53 and MDM2 proteins-interaction-inhibitor (racemic)；p53-and-mdm2-proteins-interaction-inhibitor-racemic | C40H49Cl2N5O4 | 939983-14-9 | Details |
| OT-R antagonist 2；Oxytocin receptor antagonist 2 | C28H29N3O4 | 364071-16-9 | Details |
| Pasireotide；SOM 320;SOM 230 | C58H66N10O9 | 396091-73-9 | Details |
| PD-159020 | C32H25NO8 | 177904-00-6 | Details |
| PD-1-IN-17 | C13H22N6O7 | 1673560-66-1 | Details |
| PDD00031705 | C20H22N6O3S3 | 2032096-45-8 | Details |
| CA-170；PD-1-IN-1 | C12H20N6O7 | 1673534-76-3 | Details |
| PAT-1251 Hydrochloride | C18H18ClF4N3O3 | 2098884-53-6 | Details |
| Pasireotide pamoate；SOM230 pamoate | C58 H66 N10 O9 . C23 H16 O6 | 396091-79-5 | Details |
| Azathioprine；BW 57-322 | C9H7N7O2S | 446-86-6 | Details |
| Pargolol hydrochloride；Ko 1400 hydrochloride | C16H24ClNO3 | 36902-82-6 | Details |
| PAT-505 | C23H18ClF2N3O2S | 1782070-22-7 | Details |
| Paxilline | C27H33NO4 | 57186-25-1 | Details |
| PDE2/PDE10-IN-1 | C15H10ClN5 | 1426833-08-0 | Details |
| PD-1-IN-18 | C11H17N5O8 | 1673534-97-8 | Details |
| PD-1-IN-22 | C25H25N5O4 | 2349372-98-9 | Details |
| PDE-9 inhibitor | C22H27N5O2 | 1082743-70-1 | Details |
| PDE1-IN-3 | C18H24N4O | 2370966-46-2 | Details |
| PDE5-IN-2 | C25H21N3O6S | 2244517-61-9 | Details |
| PAβN dihydrochloride；MC-207,110 dihydrochloride;Phe-Arg-β-naphthylamide dihydrochloride | C25H32Cl2N6O2 | 100929-99-5 | Details |
| Pasireotide L-aspartate salt；SOM230 L-aspartate | C62H73N11O13 | 396091-77-3 | Details |
| PD0176078 | C23H30F2N2O | 248922-46-5 | Details |
| PD1-PDL1-IN 1 | C14H23N7O6 | 2005454-12-4 | Details |
| PAT-1251 | C18H17F4N3O3 | 2007885-39-2 | Details |
| PD-1/PD-L1-IN 5 TFA；PD-1/PD-L1-IN 5 | C24H19F3N4O5S | 2170209-52-4 | Details |
| PD 90780 | C19H14N4O4 | 77422-99-2 | Details |
| Fezagepras sodium；PBI-4050 sodium salt;Setogepram sodium salt | C13H19NaO2 | 1254472-97-3 | Details |
| Parsaclisib；INCB050465 | C20H22ClFN6O2 | 1426698-88-5 | Details |
| PDE12-IN-3 | C29H25N5O3 | 1803357-22-3 | Details |
| PDE1-IN-2 | C16H21BrN4O2 | 1904611-63-7 | Details |
| PDE9-IN-1 | C17H23FN6O2 | 2305087-92-5 | Details |
| Daidzein；Isoflavone | C15H10O4 | 486-66-8 | Details |
| Indacaterol maleate；QAB149 | C28H32N2O7 | 753498-25-8 | Details |
| PC945 | C38H37F3N6O3 | 1931946-73-4 | Details |
| PARP-2-IN-1 | C21H19F4N5O3 | 2115698-83-2 | Details |
| PD 168568 dihydrochloride | C22H28ClN3O | 1782532-06-2 | Details |
| PARP14 inhibitor H10 | C24H27N7O7S | 2084811-68-5 | Details |
| PARP/PI3K-IN-1 | 2337386-47-5 | Details |
| Parcetasal；MR-897 | C17H15NO5 | 87549-36-8 | Details |
| PD 123319 ditrifluoroacetate | C33H33F3N4O5 | 136676-91-0 | Details |
| Product Total： Product Page： | ||||
| 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 | ||||